Skip to content

Released Nov 7, 2024, before the open

10-Q filed Nov 7, 2024, 38 days after period end · 0000950170-24-122782

Q3 2024 · 10-Q
Revenue$196.61M+6.8% vs Q3 2023−1.0% vs Q2 2024
Net Income-$27.39MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.71N/M vs Q3 2023N/M vs Q2 2024
Gross Profit$135,053,000+12.8%
Operating Income-$18,899,000N/M
Operating Cash Flowderived$11,671,000+2,346.8%
Free Cash Flowderived$6,349,000N/M
Margins · derived
Gross margin68.7%+3.6 pt vs Q3 2023
Operating margin-9.6%+3.7 pt vs Q3 2023
Net margin-13.9%+1.8 pt vs Q3 2023

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Revenue$196.61M$184.01M$114.00M$112.43M
Net Income-$27.39M-$28.86M-$10.72M-$2.17M
EPS Diluted-$0.71-$0.77-$0.53$0.11

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR